

## **REMARKS/ARGUMENTS**

### **Status of the Claims**

Claims 1 to 63, 65 and 66 will be pending after entry of this amendment. Claims 1, 10, 11, 12, 20, 40 and 41 have been amended.

The amendments have been made to specify that the vitronectin targeted imaging agent comprises a peptide containing an Arg-Gly-Asp sequence, in accordance with the Applicant's previous election of Modified Group 1.

Applicant respectfully submits that the amendments to the claims resolve any issues of statutory double patenting, as the claims of copending application number 10/213,713 do not recite targeting agents that include any of the peptide sequences recited in amended claim 1. Thus, Applicants respectfully submit that the claims are now in condition for allowance. Moreover, to the extent any claims in the '713 application may subsequently present issues of obviousness-type or statutory double patenting, in connection with the instant application, Applicant proposes to address such issues by amendment of the claims in the '713 application, as that application is not as far along in prosecution.


**DOCKET NO.:** BMS-2201/PH-7201  
**Application No.:** 09/995,388  
**Office Action Dated:** March 15, 2005

**PATENT**  
**REPLY FILED UNDER EXPEDITED**  
**PROCEDURE PURSUANT TO 37 CFR § 1.116**

### **CONCLUSION**

Applicant believes that the present Amendment is fully responsive to the Office Action, and respectfully submits that Claims 1 to 63, 65 and 66 are now in condition for allowance. A Notice of Allowance is earnestly solicited.

Date: May 31, 2005

  
\_\_\_\_\_  
S. Maurice Valla  
Registration No. 43,966

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439